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Abstract
One of the most ambitious endeavors in the field of diabetes technology is non-invasive glu-
cose sensing. In the past decades, a number of different technologies have been assessed,
but none of these have found its entry into general clinical use. We report on the develop-
ment of a table-top confocal Raman spectrometer that was used in the home of patients
with diabetes and operated for extended periods of time unsupervised and without recalibra-
tion. The system is based on measurement of glucose levels at a ‘critical depth’ in the skin,
specifically in the interstitial fluid located below the stratum corneum but above the underly-
ing adipose tissue layer. The region chosen for routine glucose measurements was the
base of the thumb (the thenar). In a small clinical study, 35 patients with diabetes analyzed
their interstitial fluid glucose for a period of 60 days using the new critical-depth Raman (CD-
Raman) method and levels were correlated to reference capillary blood glucose values
using a standard finger-stick and test strip product. The calibration of the CD-Raman system
was stable for > 10 days. Measurement performance for glucose levels present at, or below,
a depth of ~250μm below the skin surface was comparable to that reported for currently
available invasive continuous glucose monitors. In summary, using the CD-Raman technol-
ogy we have demonstrated the first successful use of a non-invasive glucose monitor in the
home.
Introduction
Diabetes mellitus, in its different forms, is affecting an increasing number of individuals and
placing undue strain on national health care budgets. Estimates (from 2015) state that 415 mil-
lion people worldwide suffer from diabetes whilst this number is predicted to increase to 642
million by 2040 [1]. For control of treatment the self-monitoring of blood glucose is recom-
mended, which is usually performed with an invasive finger-prick method. In Type 1 diabetes
patients dosing of insulin is frequently based on 4 to 6 blood glucose determinations per day.
For these reasons, it has been a long term goal to develop truly non-invasive techniques to
measure the blood glucose levels of diabetes patients. The current clinical trend favors indwell-
ing Clarke-type (i.e., electrochemical) sensors that allow for continuous glucose monitoring in
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a minimally-invasive way [2,3]. However, a skin puncture is still required, with associated dis-
comfort for the user and increased risk of infection; whilst these sensors also suffer from a
biocompatibility issue that limits their life to a few weeks [4].
For many decades it has been a goal to develop non-invasive techniques to measure the
blood glucose levels of diabetes patients but practical solutions for general use have so far not
been developed. The majority of approaches have been based on optical measurement of glu-
cose in tissues such as the skin [5,6,7]. Amongst these the spectroscopic techniques, such as
fluorescence, absorbance and Raman have attracted considerable attention. Despite the fact
that inelastic Raman scattering is a weak process and thus results in a poor signal the associated
high chemical specificity, minimal interference from tissue water content and only a modest
fluorescence background render the technique one of the most promising candidates for non-
invasive glucose monitoring [8]. Since the first feasibility study of measuring blood glucose
with near-infrared Raman spectroscopy in 1997 [9] several groups have substantiated this
claim by quantitative measurements of glucose levels in vivo [10–14]. These reports may be
considered proof-of-concept only in the sense that all measurements were performed in a con-
trolled environment whilst the predictive capabilities of the calibration model were assessed by
cross-validation only.
In this paper we describe the design and development of a table-top, confocal near-infrared
Raman instrument for intermittent glucose determination. The instrument uses a new princi-
ple of critical-depth Raman where measurements are taken from interstitial fluid within a
defined region of the skin. It is worth noting that in contrast to previous work that also utilizes
a confocal setup to probe in the living part of the skin [10,14], the current work is the first of
its kind to systematically study the relation between probing depth and prospective perfor-
mance of the Raman-based glucometer, thus allowing us to define a critical depth from which
the Raman signal should be acquired. Moreover, we report on the first uncontrolled study
where the system has been used by patients with diabetes in their home over a period of 60
days to obtain accurate blood glucose measurements.
Materials and methods
Instrumentation
The spectra were recorded using a custom-built confocal Raman setup of external dimensions
475mm (l) x 212mm (h) x 361mm (w). Fig 1 displays a schematic diagram of the internal
components.
The laser light is generated by a continuous-wave diode laser that emits at a wavelength of
830nm with a power of 300mW (I0830MU0350MF-NL from Innovative Photonic Solutions,
New Jersey, USA). Before the laser light interacts with the skin, it is first collimated and sent
through a clean-up filter to remove unwanted spectral side lobes and background fluorescence.
Then, the excitation light is redirected by a dichroic mirror and strongly focused onto the the-
nar (base of the thumb) by the probe lens (f-number = 0.55). The thenar is placed on a 500μm
thick magnesium fluoride window that is the only opening in the otherwise opaque cover. The
interaction of the excitation light with the skin generates Rayleigh scattered light, as well as
broadband fluorescence background, and molecule-specific Raman photons; these are all col-
lected and collimated by the probe lens. The Rayleigh light, however, is suppressed by the
dichroic mirror and the long-pass filter, only allowing wavelengths above 850nm to reach the
spectrometer slit. Before the light enters the spectrometer, it is focused onto the 50μm x 100μm
entrance slit that also functions as the pinhole in our confocal setup. The spectrometer has a f-
number of 1.3 with a spectral resolution of 9cm-1 in the measurement range of 300-1800cm-1
(custom-configured WP830 spectrometer from Wasatch Photonics, North Carolina, USA).
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The charge-coupled detector (1024x64 pixels) within the spectrometer is temperature stabi-
lized at 15˚C. It should be noted that all filters and mirrors are from Semrock (New York,
USA), while lenses are custom-made in order to minimize optical aberrations and maximize
the throughput.
The depth selectivity in our device is a consequence of the confocal design, wherein the
focus/collection depth (the ‘critical depth’, or CD) below the skin surface can be controlled by
changing the distance between the probe lens and the reference plane of the hand (see Fig 1).
In this study, we used a distance range of approx. 150 to 300μm from the reference plane at the
skin surface to the focus point in the interstitial fluid. An illustration of the expected Raman
signal density distribution in the skin (calculated as the square of the incident flux) is shown in
Fig 2 for CDs of 150, 200, 250, and 300μm.
The simulation was obtained by modelling the Raman signal in Zemax OpticStudio 16.5
(Zemax LLC, Seattle, WA), where the surface roughness and inhomogeneity of the skin are
addressed by including Trowbridge-Reitz surface scattering [15] and Henyey-Greenstein bulk
scattering [16]. It is important to note that the exact thickness and optical properties of the var-
ious skin layers vary between people, so Fig 2 should only be considered a general illustration
of the light-skin interaction of our optical setup and the influence of varying the CD. For fur-
ther details of the skin model, we refer to S1 Appendix. The simulations suggest that roughness
and turbidity in the skin leads to an increased volume from which Raman photons are col-
lected as the CD increases. Moreover, with the average measured stratum corneum (SC) of the
thenar encompassing the initial 166μm of the skin (see Protocol), it is clear that a larger frac-
tion of the Raman signal must originate from the interstitial compartment of the skin with
increasing CD. As the dynamic glucose signal (which reflects blood levels) is expected from
this component of the skin only, the simulations indicate that a confocal Raman-based CD glu-
cose monitor should focus and collect light from below the SC layer.
Fig 1. Schematic presentation of portable Raman spectrometer. The output from the diode laser (300mW
continuous power) is first collimated, unwanted spectral side lobes and fluorescence are filtered, then redirected by the
dichroic mirror and finally focused (by the f/0.55 lens) just below the skin surface. Whilst both the intense reflected/
scattered light, fluorescence, and generated Raman photons are collected by the f/0.55 lens, the dichroic mirror and the
long-pass filter ensure that only the latter two contributions to the spectrum are focused (by the f/1.3 lens) on the
entrance slit of the spectrometer.
https://doi.org/10.1371/journal.pone.0197134.g001
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Study protocol
Raman spectra were recorded from the thenar of 41 patients with diabetes aged between 20 to
60 years recruited from Odense University Hospital, Department of Endocrinology, Denmark.
For all patients the thickness of the SC at the thenar was measured using an optical coherence
tomography system (Callisto, Thorlabs Inc. New Jersey, USA). The average SC thickness was
166 +/- 40μm (x +/- SD). Six patients with SC thickness greater than 206μm were excluded
from the subsequent data analysis. The remaining cohort of 35 patients comprised 14 males
and 21 females, of which 32 had Type 1 and 3 had Type 2 diabetes; the CD of the Raman device
was fixed for each patient according to the selection criteria described in Results and was
within the range 140 to 320μm.
The patients were equipped with our table-top CD-Raman device (as described in Fig 1)
and instructed in how to use the device at home. Each patient enrolled in the study could freely
choose the 30 days of analysis within a period of 60 days, where each analysis day included
four measurement sessions (chosen appropriately over the day); which also included reference
glucose determinations conducted in capillary blood with HemoCue 201 RT (HemoCue AB,
A¨ngelholm, Sweden). Each session consisted of two subsessions with acquisition times of 2
and 1 minute respectively and the resulting Raman spectrum was a weighting of the two spec-
tra according to the acquisition times. It should be noted that the total acquisition time of 3
minutes is chosen based on performance, whereas the influence of the split has not been inves-
tigated in this study. Between the two subsessions the hand was removed from the device to
ensure that the prospective performance was not critically dependent on achieving a precise
measurement site on the thenar. As it is of paramount importance in real-life usage that the
calibration model can encompass such lateral variations in measurement site on the thenar, we
have made no attempt to quantify (or restrict) the scale of displacement between subsessions
Fig 2. Simulation of signal acquisition density distribution. Panels (A)-(D) show the simulated density distribution
of the generated Raman signal in the skin for collection depths of 150, 200, 250, and 300μm, respectively. The skin is
modelled as a turbid medium featuring both bulk and surface scattering.
https://doi.org/10.1371/journal.pone.0197134.g002
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and sessions. It should be noted that accidental movement of the hand during acquisition is
not detected on-the-fly, but it always results in error-prone spectra that can be removed during
data analysis. The study was approved by the National Danish Committee on Health Research
Ethics and the Danish Medicines Agency, and there is written consent from all the partici-
pants. The study protocol is publicly available at ClinicalTrials.gov, identifier NCT03368209.
Data analysis
The analysis of the measured Raman spectra and the correlation to blood glucose levels was
centralized in Matlab R2017a (MathWorks, Natick, Massachusetts, USA) using the PLS
Toolbox (Eigenvector Research Inc., Manson, Washington, USA).
As a first step, we excluded saturated spectral data and error-prone spectra due to misplace-
ment of hand or interference from ambient light. Secondly, measurement sessions where the
blood glucose reference was reported to exceed 30 mmol/L were excluded to conform with the
consensus error grid [17] and the measurement range of the reference glucometer Hemocue
201RT. No other data exclusion criteria were used in this study, and the remaining Raman
spectra used in the following data analysis can be found in S1 Dataset with S2 Appendix giving
an accompanying description of the different data fields.
After data capture the spectra were first smoothed by a 15-point Savitsky-Golay 1st order
algorithm, then corrected for varying intensities and backgrounds using 6th order EMSC
(extended multiplicative scatter correction [18]), and finally mean-centered. The reference
blood glucose concentrations were mean-centered prior to analysis. We note that both the
number of points used for smoothing and the EMSC order are rather high, but the values are
chosen based on overall optimal predictive performance of the calibration models. We foresee
that future implementation of outlier detection techniques may reduce these parameter values.
For the quantitative evaluation of our CD-Raman glucometer the data was divided into a
calibration set (initial 25 days of analysis) and an independent validation set (final 5 days of
analysis), with the correlation between Raman spectra and blood glucose concentrations being
determined through partial least squares (PLS) regression. The choice of 25 calibration days is
a consequence of the PLS models improving up to this point. Based on the calibration set we
calculated a PLS model for each patient, where the optimal number of latent variables (LVs)
was determined from simultaneous minimization of the root-mean-square error (RMSE) of
calibration and 10-fold cross-validation (CV, contiguous blocks). For further validation (both
cross- and independent validation) of the PLS models, we evaluated the fraction of samples in
the zones of a consensus error grid, mean average relative difference (MARD), slope and inter-
cept for a best linear fit between reference and predicted glucose concentrations, correlation
coefficient R2 and RMSE. It is worth noting that the temporal behaviour and range of blood
glucose values are very dependent on the patient with diabetes. Some of the patients were very
well-regulated with glucose values in the range of 4–10 mmol/L, with occasional hyperglycae-
mic episodes, whilst others exhibited a broader glucose range of 1–30 mmol/L with hypo-, eu-,
and hyperglycaemic periods observed. The differing behaviour amongst the patients is chal-
lenging for quantifying the performance using a single validation parameter. To overcome this
problem, we have developed a composite performance parameter called Inter-Subject Unified
Performance (ISUP):
ISUP ¼ ðAþ B   MARDÞ  slope  R2  1½mM=Ymedian; ð1Þ
where A and B are the percentage distribution of samples in zone A and B in the consensus
error grid, MARD is the calculated MARD in percentage, slope is the slope of the best linear fit
in the consensus error grid, R2 is the correlation coefficient and Ymedian is the median reference
Raman spectroscopy enables non-invasive glucose monitoring
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glucose value. The composite performance parameter is evaluated on cross- or independent
validated results and is designed to weight the presence of samples in zone A and B, together
with a low MARD, a high slope and a high correlation coefficient. Furthermore, the ISUP
takes into account that the glucose levels in some patients are generally well-regulated by also
weighting the median of blood glucose concentrations.
Results
The cohort of 35 patients was assigned to 3 groups for determination of analytical performance
at depths of 140–200 μm, 240–270 μm, and 280–320 μm below the reference plane. Data quality
was expressed by the ISUP parameter as described in Methods (Data Analysis). A depth limit of
320 μm was chosen because of the gradual deterioration of the signal below this threshold. The
boxplot in Fig 3 shows the median ISUP for the three patient groups, where a score of 0.5 was
set as the threshold between acceptable and poor performance. The choice of threshold was sup-
ported by the cross-validated results for each patient, together with the regression vector of the
calibration model and a comparison with the Raman spectrum from a reference glucose solu-
tion. The performance data in Fig 3 indicates a positive correlation between the CD and ISUP.
An optimal collection depth of 250–300 μm was chosen for the subsequent study; which is con-
sistent with the simulations shown in Fig 2. It is reasonable therefore to assume that the probe
mainly collected the Raman signal from the interstitial fluid compartment below the SC.
In 15 patients, featuring ISUP above 0.5 and CD in the range of 240–320 μm, five days of
data were validated independently with reference to their capillary glucose values as described
in Methods. On the consensus error grid shown in Fig 4, the independent validations are rep-
resented with a slope of 0.69, a MARD of 25.8% with 93% of predictions in the areas A + B. A
comparison of cross- and independent validation is shown in Table 1. As the performance of
the two validation methods is nearly identical this shows the suitability of the cross-validation
method and the predictive capabilities of the generated PLS models.
Fig 3. Box plot of performance versus collection depth. 35 patients were grouped into three depth ranges as
indicated: 140–200 um, n = 14; 240–270 um, n = 12; 280–320 um, n = 9. The box shows upper and lower quartile and
median. The threshold of 0.5 was supported by the CV results and the grading of glucose similarity for the regression
vector, above this value the performance was satisfactory.
https://doi.org/10.1371/journal.pone.0197134.g003
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Fig 5 shows the results obtained from one patient (patient ID: 15), while the remaining
results for the other 14 patients can be found in S1 Fig and S2 Fig. The representative patient
was an average-performing individual with CD of 250μm, ISUP of 1.9 and MARD from inde-
pendent validation of 27.6%. Fig 5A shows a comparison between the average Raman spec-
trum from the thenar, the spectrum of a glucose reference solution and the regression vector
of the PLS calibration model. It is seen that the presence of glucose is not immediately evident
in the raw thenar spectrum, which consists of a broad fluorescence background overlaid by
mainly skin-specific Raman peaks. In contrast, the regression vector shows clear spectral
Fig 4. Independent validation of the last five days of analysis. The measured glucose concentrations are plotted as a
function of reference values in a consensus error grid. The measurement critical depth was 240–320 um and the ISUP
was greater than 0.5.
https://doi.org/10.1371/journal.pone.0197134.g004
Table 1. Performance of cross-validated (CV) and independent validations (IV).
CV IV
MARD (%) 27.3 25.8
Slope 0.65 0.69
A (%) 54.1 58.3
B (%) 39.8 35.2
C (%) 5.4 5.9
D (%) 0.7 0.6
E (%) 0 0
Number of samples 1530 338
Patients 15 15
https://doi.org/10.1371/journal.pone.0197134.t001
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signatures of glucose, with significant peaks at the glucose-specific Raman bands at 514 cm-1
and 1123 cm-1. Fig 5B shows the measurements from the independent validation set as a func-
tion of time from the last day of calibration. For this patient the last five days of analysis
extended over a period of ten days in total and it is clear that the predictive performance did
not deteriorate during this time; thus, calibration was stable for at least 10 days.
Discussion
In the present paper we report on the development of a table-top confocal, critical-depth
Raman spectrometer that can be used in the home of patients with diabetes and operated for
extended periods of time (at least 60 days) without supervision. In a small clinical study, we
have shown that the resulting Raman spectra obtained from the thenar of 35 patients with dia-
betes can be correlated with blood glucose values; demonstrating that, with spectral data col-
lection at a depth of approx. 250μm the analytical capabilities of CD-Raman were
unambiguously verified with a calibration that is maintained for at least 10 days. The existence
of a critical measurement depth is in line with the broadly accepted view that it is necessary to
probe beyond the SC to measure dynamic glucose levels. Probing beyond depths of ~300μm
has not been investigated in this work due to the decreasing Raman signal for increasing prob-
ing depths (a consequence of skin turbidity) and the risk of an unwanted signal from the
underlying adipose tissue. We also note that the calibration may be valid for more than 10
days, but the currently acquired data doesn’t support a claim exceeding this time frame.
Selecting data obtained with a critical depth of greater than 240μm and ISUP larger than 0.5
gave an independent validation of 93% for readings in zone A and B of the consensus error
grid and an overall MARD of 25.8%; a performance that is close to current invasive continuous
monitoring devices that typically show a MARD between10-30% and 90–98% reading in zone
A+B [2,3].
In general, there are several factors which can influence the accuracy by which the CD-Ra-
man system can measure interstitial glucose concentration. One such factor is the time lag of
changes in glucose concentration between the capillary and interstitial compartments that
may vary in relation to glucose diffusion kinetics. It is generally accepted that the interstitial
Fig 5. Raman spectrum and independent predictions for an average-performing patient. (A) Average Raman
spectrum from the thenar region (blue), Raman spectrum of glucose in an aqueous solution (red), and regression
vector of PLS calibration model (black). (B) Plot of the independently predicted glucose concentration and the
reference value as a function of time from the last day of calibration. The dashed lines are for guidance only.
https://doi.org/10.1371/journal.pone.0197134.g005
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glucose concentration is delayed in comparison with the blood value during transient situa-
tions [19,20]. The time lag has been reported to be up to 45 minutes, depending on measure-
ment site and technique used [21]. Lag time associated with the IF compartment, just below
the SC, is most likely close to 5 minutes [22]. Finally, a considerable bias can be introduced by
the capillary reference method [23,24].
As we have shown, calibration is based on an individual PLS model for each patient. For
the further development of the CD-Raman system it will be necessary to establish a global cali-
bration strategy that can deal with the individual characteristics of patients, including differ-
ences in the optical properties of the skin. We are currently investigating the possibilities for
applying machine learning techniques, categorization and non-linear regression models.
[12,25].
In conclusion, this small clinical study using CD-Raman to measure interstitial glucose sug-
gests that a paradigm shift in diabetes care is now within reach. We are currently designing
extended clinical trials that will be used to further evaluate the success of this new spectro-
scopic approach. In the future we will be miniaturizing the Raman setup to reduce the foot-
print of the device and eventually allow wearable devices for non-invasive continuous
monitoring of blood glucose levels, as discussed previously by M. S. Wro´bel [8].
Supporting information
S1 Fig. Raman spectra and regression vectors for 14 patients featuring an ISUP above 0.5
and a critical depth in the range of 240–320 μm.
(TIF)
S2 Fig. Independent prediction of glucose concentration and the reference value as a func-
tion of time from the last day of calibration for 14 patients, all featuring an ISUP above 0.5
and a critical depth in the range of 240–320 μm.
(TIF)
S1 Appendix. Detailed description of the skin model used in simulations.
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